Claire Dearden - Concepedia

Author

Claire Dearden

Also Known As

C DEARDEN, C Dearden, C E Dearden, C. Dearden, C. E. Dearden, C.E. Dearden, Chris Dearden, Claire Dearden, Claire E Dearden, Claire E. Dearden

249

Publications

10.2K

Citations

H-Index

Concepts

All Affiliations

Royal Marsden Hospital Institute of Cancer Research Royal Marsden NHS Foundation Trust Heartlands Hospital The University of Texas MD Anderson Cancer Center

About

Claire Dearden is an author at Royal Marsden Hospital specializing in medicine, oncology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	29	1.9K
2	Health Sciences	4	4	297
3	Cell Biology	2	2	30
4	Public Health	1	1	11
5	Blood Transplantation	1	1	57

Claire Dearden

Publications

7.9K

Citations

H-Index

Page 1

	Year	Citations
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia John C. Byrd, Jennifer R. Brown, Susan O’Brien, New England Journal of Medicine	2014	1.6K
Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia E Matutes, V Brito-Babapulle, John Swansbury, Blood	1991	485
A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia Maria Chiara Di Bernardo, Dalemari Crowther-Swanepoel, Peter Broderick, Nature Genetics Genome-wide Association StudyDisease SusceptibilityChronic Lymphocytic LeukemiaMedicineGenetics	2008	359
High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H Claire Dearden, Estella Matutes, Bruno Cazin, Blood	2001	315
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia Michael R. Grever, Omar Abdel‐Wahab, Leslie A. Andritsos, Blood	2016	271
Long‐term follow‐up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis Monica Else, Claire Dearden, Estella Matutes, British Journal of Haematology	2009	264
Mutational Status of the <i>TP53</i> Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial David González, Pilar Martı́nez, Rachel Wade, Journal of Clinical Oncology	2011	263
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia Paul M. Barr, Carolyn Owen, Tadeusz Robak, Blood Advances Ibrutinib Vs 9Chronic Lymphocytic LeukemiaImmunologyPharmacotherapyFirst-line Ibrutinib Treatment	2022	246
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia Robert J. Kreitman, Claire Dearden, Pier Luigi Zinzani, Leukemia	2018	233
Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk Dalemari Crowther-Swanepoel, Peter Broderick, Maria Chiara Di Bernardo, Nature Genetics Hematological MalignancyAllelic VariantOncologyMedicineGenetics	2010	224

Page 1